NovoCure (NASDAQ: NVCR) HR chief granted shares, options and executes tax sale

Rhea-AI Filing Summary

NovoCure Ltd's Chief Human Resources Officer, Michal Nath Puri, reported equity compensation and a related tax sale. On March 3, 2026, he received 40,100 ordinary shares as restricted share units that vest over three years and 58,672 stock options vesting over four years. On March 4, 2026, he sold 1,100 ordinary shares at a weighted average price of $13.3054 in a mandated “sell to cover” transaction to satisfy tax withholding, and held 201,322 ordinary shares directly afterward.

Insider Trade Summary

Net Seller: 1,100 shares ($14,636)

Net Sell 3 txns

Insider Puri Michal Nath

Role Chief Human Resources Officer

Sold 1,100 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,100	$13.3054	$15K
Grant/Award	Stock Option (Right to Buy)	58,672	$0.00	--
Grant/Award	Ordinary Shares	40,100	$0.00	--

Holdings After Transaction: Ordinary Shares — 201,322 shares (Direct); Stock Option (Right to Buy) — 58,672 shares (Direct)

Footnotes (1)

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puri Michal Nath

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		A		40,100	A	$0.00	202,422	D
Ordinary Shares	03/04/2026		S		1,100(2)	D	$13.3054(3)	201,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.3	03/03/2026		A		58,672		(4)	03/03/2036	Ordinary Shares	58,672	$0.00	58,672	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

3. This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.

4. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Remarks:

	Steven Robbins, as attorney in fact for Puri, Michal Nath	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NovoCure (NVCR) report for Michal Nath Puri?

NovoCure reported that Chief Human Resources Officer Michal Nath Puri received equity awards and executed a small tax-related share sale. He was granted restricted share units and stock options, then sold 1,100 ordinary shares solely to cover tax withholding obligations tied to vesting awards.

How many NovoCure (NVCR) shares did Michal Nath Puri sell and at what price?

He sold 1,100 ordinary shares at a weighted average price of $13.3054 per share. The sale was executed in multiple trades between $13.21 and $13.445 and was required to satisfy tax withholding on vested restricted stock units under NovoCure’s equity plans.

Were Michal Nath Puri’s NovoCure (NVCR) share sales discretionary trades?

No. The 1,100-share sale was mandated by NovoCure’s award agreement as a “sell to cover” transaction. It was executed solely to fund tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary open-market decision by the executive.

What new equity awards did NovoCure (NVCR) grant to Michal Nath Puri?

He was granted 40,100 ordinary shares in the form of restricted share units and 58,672 stock options. The restricted share units vest in three equal annual installments, while the options vest in four equal annual installments, all conditioned on his continued employment with NovoCure.

How many NovoCure (NVCR) shares does Michal Nath Puri hold after these transactions?

After the reported transactions, he directly owned 201,322 ordinary shares of NovoCure. This figure reflects his holdings following the 1,100-share tax-withholding sale, as disclosed in the Form 4, and does not include the separate option position granted on the same date.

How do Michal Nath Puri’s NovoCure (NVCR) stock options vest?

The 58,672 stock options are scheduled to vest in four equal parts on the first, second, third, and fourth anniversaries of the grant date. Vesting is contingent on his continued employment with NovoCure through each applicable anniversary, according to the disclosure footnotes.